An interventional study of Standard Ureteral Access Sheath (Boston Scientific). and Flexible and Navigable Suction UAS (ClearPetra). in Pediatric Urolithiasis, Kidney Stone and Nephrolithiasis, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Among 56 studies in Kidney Calculi with a site in Egypt — 20 open to participants now, 22 under way, none of them phase 3. Kidney Calculi · Egypt.
Among the 56 studies in Kidney Calculi with a site in Egypt, this one is the 41st largest by planned enrollment of the 51 interventional ones, is one of 12 that started in 2026, is one of 48 with no phase, reaches primary completion later than 17 of the 21 other live ones, and was the 51st registered.
509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.
This study's planned enrollment of 60 is below the median of 86 across 391 interventional studies indexed under Kidney Calculi.
Browse Kidney Calculi studies →20 of the 56 studies in Kidney Calculi with a site in Egypt are open now, in 1 country. Each count lists the studies.
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →56 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 12 started in 2026.
Median enrollment 100 across the 51 interventional studies, 100 across the 5 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
1 of 56 have an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 2 studies filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
6 of the studies in Kidney Calculi with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05738304Al-Azhar UniversityUreteral Stenting After Retrograde Intrarenal Surgery for Renal Stones | 2026-11-01 |
| NCT07295860Mansoura UniversityFANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial | 2027-01-01 |
| NCT07749807Benha UniversityNebulized Glubran 2-Assisted Tubeless PCNL Versus Conventional PCNL | 2027-02-01 |
| NCT07516535Ain Shams UniversityDISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones | 2027-04-30 |
| NCT07689565Tanta UniversityStandard Versus Flexible and Navigable Suction Ureteral Access Sheath in Pediatric Flexible Ureterorenoscopy for Renal Stones < 2 cm | 2027-06-01 |
Among the 56 studies in Kidney Calculi with a site in Egypt, from their registry updates:
This randomized controlled trial aims to compare the efficacy and safety of a Flexible and Navigable Suction Ureteral Access Sheath (FANS) versus a standard ureteral access sheath during flexible ureterorenoscopy (FURS) in pediatric patients with renal stones less than 2 cm. The study will evaluate stone-free rates. operative time. intraoperative parameters. operative and postoperative complication and the need for any auxiliary procedures. Sixty pediatric patients will be randomly allocated into two equal groups and treated at the Urology Department, Tanta University.
Pediatric urolithiasis is an increasingly recognized condition associated with substantial morbidity and recurrence risk. Flexible ureterorenoscopy has become an established minimally invasive treatment option for renal stones smaller than 2 cm. The use of ureteral access sheaths facilitates repeated upper urinary tract access and may improve operative efficiency; however, concerns regarding ureteral trauma remain.
Recently developed suction-assisted ureteral access sheaths have been introduced to improve visibility, facilitate fragment evacuation, and reduce intrarenal pressure. Although promising results have been reported in adults, evidence in pediatric patients remains limited.
This prospective randomized controlled trial will compare a standard ureteral access sheath with a Flexible and Navigable Suction Ureteral Access Sheath (FANS) in pediatric patients undergoing flexible ureterorenoscopy for renal stones less than 2 cm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard UAS (Length: 28-35 cm, Size: 10/12 Fr or 9.5/11.5 Fr) used during flexible ureteroscopic stone fragmentation using Holmium:YAG laser.
Device: Standard Ureteral Access Sheath (Boston Scientific).
Suction evacuation ureteral access sheath (Length: 30-35 cm, Size: 10/12 Fr or 11/13 Fr) with terminal flexible end enabling continuous drainage and suction during laser stone fragmentation
Device: Flexible and Navigable Suction UAS (ClearPetra).
Standard UAS (Length: 28-35 cm, Size: 10/12 Fr or 9.5/11.5 Fr)
Suction evacuation ureteral access sheath (Length: 30-35 cm, Size: 10/12 Fr or 11/13 Fr) with terminal flexible end
Stone-free rate (SFR)
Absence of residual fragments or presence of clinically insignificant residual fragments measuring \< 3 mm, assessed by postoperative CT scan.
Time frame: 1 month postoperatively
Operative time
Time frame: Intraoperatively . from insertion of sheath
Intraoperative visibility and ease of access
Intraoperative visibility and ease of access using scale (good-moderate-poor)
Time frame: intraoperatively
Intraoperative complications
Time frame: intraoperatively
Postoperative complications
Postoperative complications (according to Clavien-Dindo classification).
Time frame: up to 30 days postoperatively
Need for auxiliary procedures.
This outcome measure will evaluate the requirement for additional interventions to achieve complete stone clearance or manage residual fragments. It will be assessed by recording the percentage of participants who require any secondary or ancillary surgical procedures (such as second-stage ureterorenoscopy, shock wave lithotripsy, or temporary stenting) within 30 days postoperatively
Time frame: up to 30 days postoperatively
Length of hospital stay.
The duration of hospitalization will be calculated in days, from the date of the participant's admission/surgery until the actual date of discharge from the hospital
Time frame: From the day of surgery up to hospital discharge (estimated average of 3 days)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 11 months later.
Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 11 months is below that.
Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.